Operating Income (Loss) of Acurx Pharmaceuticals, Inc. from 30 Jun 2024 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Acurx Pharmaceuticals, Inc. quarterly Operating Income (Loss) in USD history and change rate from 30 Jun 2024 to 30 Sep 2025.
  • Acurx Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending 30 Sep 2025 was $2,028,701, a 28% increase year-over-year.
Source SEC data
View on sec.gov
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)

Acurx Pharmaceuticals, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $2,028,701 +$797,897 +28% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $2,269,683 +$1,852,925 +45% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025 2025 Q2
Q3 2024 $2,826,598 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $4,122,608 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025 2025 Q2
* An asterisk sign (*) next to the value indicates that the value is likely invalid.